Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 23:21:e920948.
doi: 10.12659/AJCR.920948.

Metastatic Lung Cancer Presenting as Monocular Blindness and Panhypopituitarism Secondary to a Pituitary Metastasis

Affiliations
Case Reports

Metastatic Lung Cancer Presenting as Monocular Blindness and Panhypopituitarism Secondary to a Pituitary Metastasis

Kelsey H Sheahan et al. Am J Case Rep. .

Abstract

BACKGROUND Sellar masses are most commonly pituitary adenomas, however, about 1% of surgical resected pituitary lesions are found to be metastatic disease. It is hard to distinguish pituitary adenomas from metastatic disease. The most common primary sources for pituitary metastases are breast and lung cancer. CASE REPORT In this paper, we report the case of a woman who presented with right-sided vision loss who was found to have a sellar mass and panhypopituitarism. Subsequent imaging showed a large mass in her left upper lung with additional lesions in the spleen and adrenal glands. Neurosurgery performed an urgent transsphenoidal resection, with pathology confirming lung adenocarcinoma. CONCLUSIONS This is an unusual presentation of metastatic lung cancer, with the patient's primary symptoms being related to her pituitary metastasis and panhypopituitarism. Pituitary metastases are most commonly asymptomatic, although they can present with visual disturbances, diabetes insipidus, or panhypopituitarism. Pituitary metastases should be on the differential for sellar masses, particularly with specific radiographic findings, visual disturbances, and/or the presence of diabetes insipidus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Matthew P. Gilbert has worked as a consultant for Novo Nordisk and Sanofi, USA. Kelsey H. Sheahan, Gunnar C. Huffman, and John DeWitt declare that there are no conflicts of interest regarding the publication of this article

Conflict of interest

Matthew P. Gilbert has worked as a consultant for Novo Nordisk and Sanofi, USA. Kelsey H. Sheahan, Gunnar C. Huffman, and John DeWitt declare that there are no conflicts of interest regarding the publication of this article.

Figures

Figure 1.
Figure 1.
(A) Axial and (B) coronal magnetic resonance imaging showing “expansile sellar and suprasellar mass which measures 22×20×19 mm” (arrows).
Figure 2.
Figure 2.
Computed tomography chest with contrast that highlights the 5.3×4.0 cm left upper lobe mass (arrow) that “abuts and may invade the left mediastinum”.
Figure 3.
Figure 3.
(A, B) Histology shows gland-forming carcinoma cells (lower left) invading normal anterior pituitary tissue (upper right). Mitoses are apparent at higher power (arrows in B). Tumor cells are positive for CK7 (C) and TTF-1 (D), consistent with adenocarcinoma of lung origin.

Similar articles

Cited by

References

    1. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am. 2008;37:151–71. - PubMed
    1. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894–904. - PMC - PubMed
    1. Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am. 1999;28:81–117. - PubMed
    1. Zoli M, Mazzatenta D, Faustini-Fustini M, et al. Pituitary metastases: Role of surgery. World Neurosurg. 2013;79:327–30. - PubMed
    1. Javanbakht A, D’Apuzzo M, Badie B, et al. Pituitary metastasis: A rare condition. Endocr Connect. 2018 [Epub ahead of print] - PMC - PubMed

Publication types

Supplementary concepts